glp 1/gip receptor agonist Dual GLP-1/GIP | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Science Behind GLP 1 GIP

Lilly is studying retatrutide across obesity, type 2 diabetes, cardiovascular risk, and related conditions

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and obesity, have shown promise in modulating reward-related brain pathways, suggesting potential benefits in the management of AUD

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of agents that have evolved rapidly in recent years

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health